Bronchenolo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bronchenolo

Property Description
Active Ingredient Dextromethorphan HBr, Guaifenesin
Form Oral Solution (Syrup), Lozenges, Tablets
Pharmacological Class Antitussive and Expectorant
Common Purpose Symptomatic relief of cough and mucus congestion
Origin Synthetic/Derived

Bronchenolo is a proprietary brand name for a combination medicine formulated for the symptomatic relief of coughs and associated respiratory irritation. It is an Over-the-Counter (OTC) preparation intended for oral administration and is defined by its identity as a dual-action formulation that provides both suppressive and expectorant effects. Its positioning often targets relief for the dual discomforts experienced during a typical cold, such as a scratchy throat and heavy chest.

Bronchenolo: A Dual-Action Antitussive and Expectorant

Bronchenolo is pharmacologically defined as an Antitussive and Expectorant preparation, a classification that highlights its core function to both quiet a cough and aid in clearing the airways. The product combines two distinct active substances: Dextromethorphan Hydrobromide and Guaifenesin. Dextromethorphan acts as a centrally acting cough suppressant that modulates the cough reflex. This means the medicine works to reduce the activity in the area of the brain that triggers the cough.

What is the Composition and Pharmaceutical Form of Bronchenolo?

The core active ingredients, Dextromethorphan Hydrobromide and Guaifenesin, are both synthetic or derived compounds. Guaifenesin functions by thinning respiratory secretions, an action that helps make thick mucus easier to clear from the airways. The medicine is commonly available as an oral solution (syrup), which allows for rapid absorption, and in solid forms such as lozenges or tablets, providing choice for consumer preference regarding convenience and taste. The formulation is often distinctively flavored to enhance patient acceptability of the oral forms.

What General Symptom Relief Does Bronchenolo Provide?

The formulation’s primary function is to offer symptomatic relief by calming the persistent urge to cough, especially when non-productive, while simultaneously facilitating the expulsion of mucus. A typical use scenario for Bronchenolo involves managing the shift from a dry, irritating cough at the onset of a cold to the subsequent need to clear chest congestion. By promoting mucus fluidization, the Guaifenesin component helps transition the cough into a more effective means of clearing the respiratory tract. The Dextromethorphan component ensures that this process is achieved with reduced discomfort from continuous, irritating coughing.

Regulatory References

  1. clinically recognized in pharmacological studies

What side effects are possible with Bronchenolo?

Possible Side Effects and Safety Information

The safety profile of the Dextromethorphan/Guaifenesin combination is based on adverse reactions and constraints documented in official regulatory labeling. Side effects are typically categorized by the body system affected, with common effects related to the gastrointestinal and nervous systems.

Documented Adverse Reactions

Adverse reactions frequently listed in regulatory documents include nausea, vomiting, diarrhea, stomach pain, dizziness, headache, and drowsiness. Effects on the central nervous system may also include nervousness, restlessness, and insomnia.

Clinically Significant Safety Concerns

The regulatory label specifies certain events that signal the need to discontinue use and seek professional attention. These include signs of hypersensitivity or allergic reactions (such as a rash or hives). Additionally, a persistent cough for more than seven days, a recurring cough, or a cough accompanied by a fever or persistent headache are defined as potential markers for a serious underlying condition.

Safety Restrictions and Special Populations

This medication is subject to several regulatory limitations. There is an absolute contraindication against its use in individuals taking or who have recently stopped (within two weeks) a Monoamine Oxidase Inhibitor (MAOI), due to the critical risk of a serious drug interaction. Use in children under 12 years of age is generally restricted for adult OTC formulations. Furthermore, specific consultation with a health professional is required if the patient is pregnant, breast-feeding, or has a persistent/chronic cough associated with conditions like asthma or smoking, according to official labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

Bronchenolo contains the cough suppressant dextromethorphan, and some formulations may also contain expectorants or local anesthetics. Overdose risk is primarily associated with the component dextromethorphan, especially when excessive amounts are consumed, or when it is combined with other central nervous system depressants or certain antidepressants.

Clinical Manifestations of Overdose

Symptoms of dextromethorphan overdose, which can occur alone or as part of a combination product overdose, often involve the central nervous system. Documented clinical manifestations can include mental status changes such as agitation, confusion, hallucinations, and psychosis, alongside physical effects such as drowsiness, dizziness, loss of muscle coordination (ataxia), and seizures.

More severe overdose can lead to marked respiratory depression (breathing problems), coma, and changes in vital signs, including elevated or unstable blood pressure and a rapid heartbeat. In cases of co-ingestion with antidepressants that affect serotonin, an overdose may result in serotonin syndrome (symptoms include restlessness, tremors, hyperreflexia, and high fever).

Required Emergency Actions

Immediate medical attention is required if an overdose is suspected or if severe symptoms are present. In the event of an accidental or intentional overdose, notify emergency services or a poison control center immediately. Medical providers in a clinical setting will monitor the patient's vital signs and may perform interventions such as providing supportive care, administering activated charcoal to reduce drug absorption, or using specific reversal agents if indicated by the co-ingested substances. Rapid medical assessment is critical for managing potentially life-threatening complications like respiratory or cardiac instability.

Therapeutic Uses of Bronchenolo

What Bronchenolo Treats: Main Uses and Benefits

This medication is generally applied for the symptomatic management of the irritating cough cycle characteristic of acute respiratory infections and the common cold. This combination is used to help address cough patterns that shift from dry and fatiguing to those associated with chest heaviness. It provides support that helps ease the overall symptom burden, particularly by temporarily relieving cough due to minor throat and bronchial irritation.

It is commonly used across conditions presenting with acute episodes like the common cold, mild tracheitis, and acute bronchitis, where symptoms create noticeable interference with daily stability. The expectorant component is used to help manage thick mucus and thin bronchial secretions, assisting with the clearance of bothersome respiratory discharge and supporting a more productive cough.

“The formulation is relevant in clinical settings marked by the heightened, transient discomfort of seasonal illnesses.”

This application supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of acute or disruptive manifestations.


Quick Fact: Relief for Dual Discomfort
Primary Focus: Addressing both the persistent, dry, irritating cough and the difficulty in clearing thickened respiratory secretions.

Regulatory References

  1. DailyMed (NIH/FDA) product labeling for Dextromethorphan and Guaifenesin

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Bronchenolo — Official Regulatory Information

Official regulatory documents define strict criteria for the use of this combination medicine (Dextromethorphan/Guaifenesin).


Populations for whom use is contraindicated:

  • Patients with known hypersensitivity to Dextromethorphan, Guaifenesin, or any excipients.
  • Patients who have taken a Monoamine Oxidase Inhibitor (MAOI) within the preceding 14 days.
  • Patients with a persistent or chronic cough associated with conditions such as asthma, emphysema, or chronic bronchitis.
  • Cough that is accompanied by excessive phlegm or secretions.

Age-Related and Condition-Specific Eligibility Rules:

  • Children Under 12 Years Old: Use is generally contraindicated or not recommended by major authorities.
  • Adults and Adolescents 12 Years and Older: Considered the eligible population for standard use.
  • Hepatic Impairment: Caution is advised for patients with moderate to severe liver dysfunction due to the hepatic metabolism of Dextromethorphan.
  • Pregnancy and Lactation: Use is generally not recommended. Patients must consult a health professional before use, as advised in regulatory warnings.
  • Metabolic Restrictions: Certain formulations are restricted for use in patients with Phenylketonuria (PKU) if they contain aspartame.

What should I know about interactions with other medicines?

The official regulatory profile for Bronchenolo, containing Dextromethorphan and Guaifenesin, identifies several categories of interacting substances and specific constraints. Co-administration is strictly contraindicated with Monoamine Oxidase Inhibitors (MAOIs) due to the documented risk of developing serotonin syndrome, a potentially fatal pharmacodynamic interaction. This restriction is governed by a mandated 14-day washout period that must be observed both before initiating the cough medicine and after its discontinuation.

A key pharmacokinetic interaction involves potent CYP2D6 inhibitors (such as Quinidine, Fluoxetine, or Bupropion). These medicinal products can significantly reduce the clearance of Dextromethorphan, leading to a substantial increase in its plasma concentrations as stated in official labeling. Individuals classified as CYP2D6 poor metabolizers exhibit inherently higher exposure to Dextromethorphan, mirroring the effect of this metabolic drug-drug interaction.

Furthermore, a pharmacodynamic constraint exists with other serotonergic agents (like SSRIs or TCAs), where combined use may contribute to an additive serotonergic load. The official documentation also requires caution regarding the co-ingestion of alcohol or other CNS depressants (e.g., sedatives or certain antihistamines), as this combination may result in additive central nervous system depression.

Mechanism of Action

The mechanism of this dual-action medicine targets two distinct physiological systems: the central control of the cough reflex and the peripheral management of airway secretions.

Central Regulation of the Cough Threshold

The core antitussive mechanism involves the ingredient Dextromethorphan modulating activity in the Cough Center of the brainstem, primarily by acting as an antagonist on NMDA receptors and modulating Sigma-1 (sigma1) receptors. These central interactions interrupt the transmission and integration of sensory signals that initiate a cough, leading to an elevated cough threshold. This mechanism is relevant for systems where targeted pathway adjustment of the central reflex is required, reducing the transmission of efferent command signals.

Peripheral Modulation of Respiratory Secretions

The expectorant action is driven by Guaifenesin stimulating peripheral sensory receptors in the gastric mucosa, which triggers the Gastro-Pulmonary Neurogenic Reflex. This vagally-mediated reflex increases parasympathetic outflow to the bronchial glands. The resulting surge in secretory activity increases the water content in the respiratory tract, which decreases mucus viscosity and elasticity. This action engages mechanisms that influence feedback regulation within the bronchial pathway, supporting a more regulated state that aids the natural clearance of secretions.

The combination produces a central modulation of the cough reflex and a peripheral change in secretion rheology.

Dosage and Administration Information

Bronchenolo (Dextromethorphan HBr and Guaifenesin) is a fixed-combination preparation for oral administration only. The application of this medication is defined by the specific form, dose, frequency, and duration of use associated with its formulation.


Administration Guidelines

Usage Constraint Parameters
Administration Route Oral administration is the designated route for all available dosage forms, including syrup, tablets, and lozenges.
Dosing (Ages 12+) Immediate-Release (Syrup): 10 mL every 4 hours. Maximum of 6 doses in 24 hours. Extended-Release (Tablet): 1 tablet every 12 hours. Maximum of 2 tablets in 24 hours.
Course Duration Use is generally limited to short-term courses. Application typically does not exceed 7 days.
Pediatric Restriction Most adult formulations, including extended-release tablets, are not indicated for children under 12 years of age.

Administration Requirements

Proper use of the medication involves specific procedural adherence. Extended-release tablets are intended to be swallowed whole with a full glass of water to support the action of the expectorant component and maintain the intended release profile. These tablets are not to be crushed, chewed, or broken. Intake is permitted without regard to the timing of meals.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bronchenolo

Evidence for Symptomatic Relief of Acute Cough

Research examining this medicine was studied for conditions characterized by fluctuating or episodic manifestations of cough associated with the common cold or other upper respiratory tract infections. The evidence base primarily consists of short-term Randomized Controlled Trials (RCTs) and Systematic Reviews that tested the individual active components (Dextromethorphan and Guaifenesin), as well as the combination. Systematic reviews have indicated that the data show patterns related to mixed findings, and evidence quality may be variable across studies.


Study Focus and Follow-up Duration

Studies explored how symptoms evolved in the observed populations by measuring patient-reported outcomes describing perceived discomfort. These outcomes were related to physical discomfort, specifically cough frequency and intensity, along with cough-related sleep quality and mucus clearance. Scientific reviews indicate that the evidence base is generally described as limited and heterogeneous. Research provided insight into short-term changes, typically over study periods lasting less than 10 days, reflecting the acute nature of the illness. Long-term effects are not fully established.


Evidence in Special Populations and Uncertainties

The research has examined different age groups, with study populations primarily including Adults (18 years and older) and Adolescents (12 years and older). However, data for certain groups remain insufficient, with research specifically focused on older adults being limited.

A key uncertainty area is the lack of extensive, high-quality comparative evidence specifically for the fixed-dose combination product against placebo. Evidence quality varies across studies, and systematic reviews have identified several research limitation frames, including that sample sizes were modest in some reports. This research provides context but does not determine whether an individual will respond similarly.

Key Studies & References

  1. Dextromethorphan Hydrobromide and Guaifenesin Oral Solution Product Labeling (Regulatory Document)
  2. Dextromethorphan Hydrobromide. In: StatPearls [Internet] (Pharmacology and Mechanism)

Frequently Asked Questions (FAQ)

Common questions about Bronchenolo (FAQ)

Q: How quickly does Bronchenolo start to work?

Official information indicates that the immediate-release form of the medication is absorbed quickly by the body. While specific onset times are not always stated on labels, clinical documentation suggests effects typically occur within the first hour after taking the product.

Q: How long does the effect of Bronchenolo usually last?

The expected duration of the medicine's effect is typically reflected in the required dosing schedule described in the product information. Official product information describes the immediate-release liquid formula as generally administered on a four-hour schedule, and extended-release tablets are generally described as having a twelve-hour dosing interval.

Q: Why is it described as an 'over-the-counter' medicine?

Bronchenolo is classified as an Over-the-Counter (OTC) medicine because its core active ingredients are recognized as safe and effective for non-prescription use by authoritative regulatory bodies. This classification is based on the final monographs established by agencies like the FDA.

Q: Are there different formulas or strengths of Bronchenolo?

Official regulatory documents confirm that this combination of active ingredients is available in different strengths and concentrations. It is also supplied in various physical forms, such as liquid syrup, lozenges, and extended-release tablets, to suit patient preference.

Q: What is the difference between Bronchenolo syrup and pastilles?

Syrup is an oral solution that allows for relatively quick absorption into the bloodstream. Solid forms like tablets or pastilles may have specific administration instructions, such as swallowing them whole without crushing or chewing, to maintain the intended controlled-release profile described in the official instructions.

Q: Are there any specific foods or drinks to avoid when using Bronchenolo?

Official labeling describes that alcohol and other medications classified as CNS depressants should be avoided due to the documented risk of additive effects. However, the medication is generally authorized to be taken without regard to the timing of meals.

Q: Does Bronchenolo interact with blood pressure medication?

The active ingredients in Bronchenolo are not typically known to raise blood pressure. However, combination cold and cough products often include other substances like decongestants, which can affect blood pressure. For this reason, regulatory guidance advises professional consultation.

Q: Is Bronchenolo usage restricted for elderly people?

Official drug labels usually do not contain specific dosage guidelines for older adults (the geriatric population). Regulatory authorities note that data focused specifically on this group is limited, which suggests that professional consultation is advised for this population.

Q: Can people with high blood pressure use Bronchenolo?

The individual active ingredients in the formula are generally not classified as problematic for people with high blood pressure. Nevertheless, official guidance advises individuals with high blood pressure to consult a health professional before using any over-the-counter combination medicine.

Q: Is Bronchenolo safe for individuals with diabetes?

The drug itself is not typically contraindicated for diabetes, but syrup and lozenge formulations often contain sugars, high-fructose corn syrup, or other sweeteners. These ingredients must be considered, which individuals with diabetes are advised to verify. Sugar-free versions are often available.

Q: Can people with liver or kidney conditions take Bronchenolo?

Official information advises caution for people with moderate to severe liver dysfunction. Although there are no specific dosage changes for kidney impairment noted in standard regulatory labels, official guidance advises consultation for patients with renal conditions.

Q: What does 'contraindication' mean in relation to Bronchenolo?

A contraindication is a circumstance where a medication is not permitted for use because the risks involved outweigh any potential benefit. In relation to this drug, contraindications include having severe hypersensitivity or taking certain other medications like MAOIs.

Q: Is Bronchenolo a narcotic or addictive substance?

Official regulatory information states that this medication is not classified as a narcotic, and its active ingredients are not scheduled by the DEA. Although Dextromethorphan is chemically related to morphine, it does not possess addictive opioid properties at therapeutic doses.

Q: What happens if you accidentally take too much Bronchenolo?

Regulatory warnings describe that a Poison Control Center should be contacted immediately if an overdose is suspected. Taking too much may result in symptoms such as excitement, confusion, dizziness, or excessive drowsiness.

Q: Where can I find the official patient information leaflet for Bronchenolo?

The official regulatory label for the product, known as the Structured Product Label (SPL), is available to the public on governmental websites. You can typically find this information on sites like DailyMed, which is maintained by the NIH and FDA.

Q: Does Bronchenolo contain sugar?

Liquid formulations often contain various sweeteners, including sucrose (sugar) or high fructose corn syrup. If the presence of sugar is a concern, users should check the inactive ingredient section or specifically look for formulations labeled as Sugar-Free.

Q: Can I use Bronchenolo if I am taking antidepressant medication?

Official documentation describes that extreme caution is advised if the patient is taking antidepressant medication, particularly those classified as Serotonin Reuptake Inhibitors (SSRIs). This is due to a serious risk of developing serotonin syndrome from additive effects.

Q: Does Bronchenolo contain alcohol?

Many non-narcotic liquid versions of the product are explicitly labeled as Alcohol Free in the inactive ingredients section. However, since alcohol is sometimes used as a solvent in certain products, the specific product’s label must always be reviewed to confirm its contents.

Q: Is Bronchenolo gluten-free?

Some manufacturers explicitly label their formulations as Gluten Free, but this is not a universal requirement for all products. If a specific 'Gluten Free' statement is not present on the package, individuals should review the full list of inactive ingredients for potential components containing gluten.

Q: Are there known interactions between Bronchenolo and common cold medications?

Official documentation advises caution when taking this medication with other common cold and flu remedies. This is because many cold medications may contain CNS depressants (central nervous system depressants, like certain antihistamines) or other cough suppressants, which can lead to additive side effects.

Q: Is it described as normal if Bronchenolo doesn't seem to work immediately?

Regulatory warnings instruct users to stop using the medication and consult a health professional if the cough persists for more than seven days, or if the cough is accompanied by a fever or persistent headache. This provides context for when symptoms that persist beyond a certain timeframe are described as a marker for seeking professional advice.

How should Bronchenolo be stored and disposed of?

How to Store and Dispose of Bronchenolo

Official regulatory labeling dictates strict rules for the storage and disposal of Bronchenolo to maintain stability and ensure environmental safety.

Mandatory Storage Requirements

Storage Component Regulatory Condition
Child Safety Must be kept out of the sight and reach of children.
Temperature The Pediatric Syrup variant must not be stored above 25°C; the general Syrup requires no special precautions.
Protection The Pediatric Syrup must be stored in its original packaging to protect from light.
Stability (Post-Opening) Varies by product: 1 year for Tosse Syrup and 1 month for Pediatric Syrup.

Official Disposal Rules

Unused or expired Bronchenolo must not be disposed of in household waste or flushed down the toilet. All product and derived waste must be discarded in conformity with local pharmaceutical waste regulations. Consult a pharmacist for specific guidance on eliminating the medicinal product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bronchenolo found in:

A-Z Index: